Jonathan R. Dry - Concepedia

Author

Jonathan R. Dry

Also Known As

Dry, Jonathan, Dry, Jonathan R, Dry, Jonathan R., J. Dry, J.R. Dry, Jonathan Dry, Jonathan R Dry, Jonathan R. Dry, William Barendt

223

Publications

Citations

H-Index

Concepts

All Affiliations

AstraZeneca (United States)AstraZeneca (United Kingdom)University of Cambridge Tempus Labs (United States)Wellcome Sanger Institute

About

Jonathan R. Dry is an author at AstraZeneca (United States) specializing in medicine, systems biology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	1.8K
2	Engineering	4	4	1.2K
3	Natural Sciences	1	1	17
4	Social Sciences	1	1	19
5	Biomedical Engineering	1	1	94

Jonathan R. Dry

Publications

3.7K

Citations

H-Index

Page 1

	Year	Citations
VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research Zhongwu Lai, Aleksandra Markovets, Miika Ahdesmäki, Nucleic Acids Research EngineeringGeneticsPathologyGenomicsHigh Throughput Sequencing	2016	1K
Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen Michael P. Menden, Dennis Wang, Mike J. Mason, Nature Communications	2019	350
Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models Catherine A. Eberlein, Daniel Stetson, Aleksandra Markovets, Cancer Research	2015	293
Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244) Jonathan R. Dry, Sandra Pavey, Christine A. Pratilas, Cancer Research Cell SubsetsTumor BiologyTranscriptional RegulationSignaling PathwayCell Regulation	2010	261
Amplification of the Driving Oncogene, <i>KRAS</i> or <i>BRAF</i> , Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells Annette S. Little, Kathryn Balmanno, Matthew J. Sale, Science Signaling	2011	204
AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies Garrett W. Rhyasen, Maureen M. Hattersley, Yi Yao, Molecular Cancer Therapeutics Azd5153 ExposurePathologyPharmacotherapyTumor BiologyMyeloid Neoplasia	2016	147
PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models Terrence F. Meehan, Nathalie Conte, Theodore C. Goldstein, Cancer Research	2017	127
Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response Ben Sidders, Pei Zhang, Kelly Goodwin, Clinical Cancer Research	2020	96
A pan-cancer organoid platform for precision medicine Brian M. Larsen, Madhavi Kannan, Lee Langer, Cell Reports EngineeringBiomedical EngineeringTumor BiologyOncologyTumor Heterogeneity	2021	94
Knowledge graph-based recommendation framework identifies drivers of resistance in EGFR mutant non-small cell lung cancer Anna Gogleva, Dimitris Polychronopoulos, Matthias Pfeifer, Nature Communications	2022	88

Page 1